ADMA Biologics Balance Sheet
NASDAQ: ADMAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ADMA Biologics financial position
At the end of fiscal 2025, ADMA Biologics reported total assets of $624.2 million, up 27.7% from a year earlier against total liabilities of $146.9 million. Shareholders' equity stood at $477.3 million, or 76.5% of assets. The company held $87.6 million in cash and equivalents against $72.1 million of debt, a net cash position of $15.5 million.
The current ratio (current assets divided by current liabilities) was 6.71, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.15.
Summary generated from market data by MetaCap's automated system. Methodology
ADMA Biologics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 87.63M | 103.15M | 51.35M | 86.52M | 51.09M | 55.92M | 26.75M | 26.75M | 43.11M | 9.91M |
| Short-Term Investments | — | — | — | — | — | — | — | — | 0 | 5.39M |
| Receivables | 158.43M | 50.00M | 27.42M | 15.51M | 28.58M | 13.24M | 3.47M | 1.39M | 3.88M | 1.02M |
| Inventory | 206.47M | 170.24M | 172.91M | 163.28M | 124.72M | 81.54M | 53.06M | 18.62M | 12.63M | 5.02M |
| Total Current Assets | 466.51M | 331.41M | 257.01M | 270.40M | 208.73M | 153.74M | 85.82M | 44.53M | 62.34M | 21.66M |
| Property, Plant & Equipment | 65.06M | 54.71M | 53.84M | 58.26M | 50.94M | 41.59M | 31.74M | 30.12M | 30.47M | 2.00M |
| Goodwill | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 0 |
| Intangible Assets | 632.00K | 460.00K | 499.00K | 1.01M | 1.73M | 2.44M | 3.16M | 4.00M | 4.85M | 0 |
| Total Assets | 624.24M | 488.68M | 329.18M | 348.46M | 276.25M | 207.67M | 127.09M | 88.88M | 108.02M | 23.69M |
| Accounts Payable | 22.52M | 20.22M | 15.66M | 13.23M | 12.43M | 11.07M | 9.17M | 5.90M | 5.92M | 2.56M |
| Short-Term Debt | 2.81M | 0 | — | — | — | — | — | — | — | — |
| Total Current Liabilities | 69.54M | 55.54M | 49.81M | 39.27M | 30.38M | 19.95M | 14.03M | 9.63M | 9.44M | 11.22M |
| Long-Term Debt | 69.33M | 72.34M | 130.59M | 142.83M | 94.87M | 92.97M | 68.29M | 26.44M | 25.37M | 12.32M |
| Total Liabilities | 146.92M | 139.66M | 193.98M | 196.49M | 135.08M | 119.42M | 100.90M | 69.11M | 67.69M | 28.14M |
| Shareholders' Equity | 477.32M | 349.02M | 135.21M | 151.97M | 141.17M | 88.25M | 26.19M | 19.77M | 40.33M | -4.46M |
| Retained Earnings | -161.65M | -308.58M | -506.26M | -478.02M | -412.11M | -340.47M | -264.72M | -216.44M | -150.69M | -106.93M |
| Total Debt | 72.14M | 72.34M | 130.59M | 142.83M | 94.87M | 92.97M | 68.29M | 26.44M | 25.37M | 12.32M |
| Net Cash (Debt) | 15.49M | 30.81M | -79.24M | -56.31M | -43.78M | -37.05M | -41.54M | 314.02K | 17.74M | 2.98M |
| Shares Outstanding | 237.87M | 236.62M | 226.06M | 221.82M | 195.81M | 104.90M | 59.32M | 46.35M | 36.73M | 12.89M |
This table shows 10 annual periods of ADMA Biologics's balance sheet, from FY 2025 back to FY 2016, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ADMA's reporting calendar. What is a balance sheet?